



Pitney Pharmaceuticals Limited

26 July 2019

The Manager Company Announcements Australian Stock Exchange Limited Via Electronic Lodgement

Dear Sir/Madam

PHARMAUST LIMITED (ASX: PAA) - SECONDARY TRADING NOTICE PURSUANT TO SECTION 708A(5)(e) OF THE CORPORATIONS ACT 2001

The Company gives this notice pursuant to section 708A(5)(e) of the Corporations Act 2001 (Cth) ("Act").

The Company has issued 1,000,000 unlisted options in the capital of the Company as per the Appendix 3B lodged with the ASX today.

The Company advises that the securities were issued without disclosure to investors under Part 6D.2 of the Act. The Company, as at the date of this notice, has complied with:

- (a) the provisions of Chapter 2M of the Act as they apply to the Company; and
- (b) section 674 of the Act.

As at the date of this notice there is no information that is excluded information for the purposes of sections 708A(7) and (8) of the Act.

Yours sincerely,

Sam Wright Company Secretary

Rule 2.7, 3.10.3, 3.10.4, 3.10.5

Appendix 3B

New issue announcement, application for quotation of additional securities and agreement

Information or documents not available now must be given to ASX as soon as available. Information and documents given to ASX become ASX's property and may be made public.

Introduced 01/07/96 Origin: Appendix 5 Amended 01/07/98, 01/09/99, 01/07/00, 30/09/01, 11/03/02, 01/01/03, 24/10/05, 01/08/12, 04/03/13

Name of entity

PharmAust Limited

ABN

35 094 006 023

We (the entity) give ASX the following information.

Part 1 - All issues

You must complete the relevant sections (attach sheets if there is not enough space).

1 +Class of +securities issued or to be issued Unlisted Options

1,000,000

- 2 Number of *securities issued or to be issued (if known) or maximum number which may be issued
- Principal of the terms 3 +securities (e.g. if options, exercise price and expiry date; if partly paid +securities, the amount outstanding and due dates for payment; if +convertible securities, the conversion price and dates for conversion)

1,000,000 Unlisted Options Expiry date 30 June 2022 Exercise Price 6.5 cents

⁺ See chapter 19 for defined terms.

4	 Do the *securities rank equally in all respects from the *issue date with an existing *class of quoted *securities? If the additional *securities do not rank equally, please state: the date from which they do the extent to which they do the extent to which they participate for the next dividend, (in the case of a trust, distribution) or interest payment the extent to which they do not rank equally, other than in relation to the next dividend, distribution or interest payment 	No – new stream of options
	. /	
5	Issue price or consideration	1 million options at an issue price of \$0.0001
6	Purpose of the issue (If issued as consideration for the acquisition of assets, clearly identify those assets)	Options issued to corporate advisors including Alto Capital under the terms of a Corporate Advisory Mandate.
6a	Is the entity an ⁺ eligible entity that has obtained security holder approval under rule 7.1A? If Yes, complete sections 6b – 6h <i>in relation to the ⁺securities the</i> <i>subject of this Appendix 3B</i> , and comply with section 6i	Yes
6b	The date the security holder resolution under rule 7.1A was passed	9 November 2018
бс	Number of *securities issued without security holder approval under rule 7.1	Nil

⁺ See chapter 19 for defined terms.

6d	Number of +securities issued
	with security holder approval
	under rule 7.1A

6e Number of +securities issued with security holder approval under rule 7.3, or another specific security holder approval (specify date of meeting)

6f Number of +securities issued under an exception in rule 7.2

6g If *securities issued under rule 7.1A, was issue price at least 75% of 15 day VWAP as calculated under rule 7.1A.3? Include the *issue date and both values. Include the source of the VWAP calculation.

6h If +securities were issued under rule 7.1A for non-cash consideration, state date on which valuation of consideration was released to ASX Market Announcements

6i Calculate the entity's remaining issue capacity under rule 7.1 and rule 7.1A – complete Annexure 1 and release to ASX Market Announcements

7 ⁺Issue dates

Note: The issue date may be prescribed by ASX (refer to the definition of issue date in rule 19.12). For example, the issue date for a pro rata entitlement issue must comply with the applicable timetable in Appendix 7A.

Cross reference: item 33 of Appendix 3B.

8 Number and +class of all +securities quoted on ASX (*including* the +securities in section 2 if applicable)

	Number	+Class	
es		Fully paid ordinary shares	
e)		310103	

Nil

Nil

Nil

N/a

n/a

See Annexure 1

26/07/2019

+ See chapter 19 for defined terms.

Appendix 3B New issue announcement

 9
 Number and +class of all
+securities not quoted on ASX
(including the +securities in
section 2 if applicable)
 Number

 10
 000
 000


21,645,412Options Ex 12c Expiry 30/11/1910,000,000options, ex 12c, expiry 31/1/225,000,000options, ex 8c, expiry 31/12/203,750,000options, ex 7.5c, expiry 31/3/207,500,000options, ex 15c, expiry 31/3/209,000,000options, ex 23c, expiry 31/3/201,000,000options, ex 6.5c, expiry 30/6/22

+Class

10 Dividend policy (in the case of a trust, distribution policy) on the increased capital (interests)

Part 2 - Pro rata issue

- 11 Is security holder approval required?
- 12 Is the issue renounceable or nonrenounceable?
- 13 Ratio in which the ⁺securities will be offered
- 14 *Class of *securities to which the offer relates
- 15 ⁺Record date to determine entitlements
- 16 Will holdings on different registers (or subregisters) be aggregated for calculating entitlements?
- 17 Policy for deciding entitlements in relation to fractions



The Company has not declared a dividend.

⁺ See chapter 19 for defined terms.

18 Names of countries in which the entity has security holders who will not be sent new offer documents

Note: Security holders must be told how their entitlements are to be dealt with.

Cross reference: rule 7.7.

19 Closing date for receipt of acceptances or renunciations

⁺ See chapter 19 for defined terms.

Names of any underwriters 20 Amount of any underwriting fee 21 or commission Names of any brokers to the 22 issue Fee or commission payable to 23 the broker to the issue Amount of any handling fee 24 payable to brokers who lodge acceptances or renunciations on behalf of security holders If the issue is contingent on 25 security holders' approval, the date of the meeting Date entitlement and acceptance 26 form and offer documents will be sent to persons entitled If the entity has issued options, 27 and the terms entitle option holders to participate on exercise, the date on which notices will be sent to option holders Date rights trading will begin (if 28 applicable) Date rights trading will end (if 29 applicable) How do security holders sell 30 their entitlements in full through a broker? How do security holders sell *part* 31 of their entitlements through a broker and accept for the balance?

⁺ See chapter 19 for defined terms.

- 32 How do security holders dispose of their entitlements (except by sale through a broker)?
- 33 ⁺Issue date

(b)

Part 3 - Quotation of securities

You need only complete this section if you are applying for quotation of securities

- 34 Type of *securities (*tick one*)
 (a) ⁺Securities described in Part 1
 - All other +securities

Example: restricted securities at the end of the escrowed period, partly paid securities that become fully paid, employee incentive share securities when restriction ends, securities issued on expiry or conversion of convertible securities

Entities that have ticked box 34(a)

Additional securities forming a new class of securities

Tick to indicate you	are providing	the information	or
locuments			

- 35 If the *securities are *equity securities, the names of the 20 largest holders of the additional *securities, and the number and percentage of additional *securities held by those holders
- 36 If the *securities are *equity securities, a distribution schedule of the additional *securities setting out the number of holders in the categories 1 1,000 1,001 5,000 5,001 10,000 10,001 100,000 100,001 100,000 100,001 and over
- 37 A copy of any trust deed for the additional ⁺securities

⁺ See chapter 19 for defined terms.

Entities that have ticked box 34(b)

38	Number of ⁺ securities for which ⁺ quotation is sought		
39	⁺ Class of ⁺ securities for which quotation is sought		
40	Do the ⁺ securities rank equally in all respects from the ⁺ issue date with an existing ⁺ class of quoted ⁺ securities?		
	 If the additional *securities do not rank equally, please state: the date from which they do the extent to which they participate for the next dividend, (in the case of a trust, distribution) or interest payment the extent to which they do not rank equally, other than in relation to the next dividend, distribution or interest payment 		
41	Reason for request for quotation now Example: In the case of restricted securities, end of restriction period (if issued upon conversion of another ⁺ security, clearly identify that other ⁺ security)		
		Number	+Class
		inumber	+Class
42	Number and ⁺ class of all		

		Number	+Class
42	Number and ⁺ class of all ⁺ securities quoted on ASX (<i>including</i> the ⁺ securities in		
	clause 38)		

⁺ See chapter 19 for defined terms.

Quotation agreement

- ⁺Quotation of our additional ⁺securities is in ASX's absolute discretion. ASX 1 may quote the ⁺securities on any conditions it decides.
- We warrant the following to ASX. 2
 - The issue of the *+*securities to be quoted complies with the law and is not for an illegal purpose.
 - There is no reason why those *+*securities should not be granted +quotation.
 - An offer of the *securities for sale within 12 months after their issue will not require disclosure under section 707(3) or section 1012C(6) of the Corporations Act.

- Section 724 or section 1016E of the Corporations Act does not apply to any applications received by us in relation to any +securities to be quoted and that no-one has any right to return any *securities to be quoted under sections 737, 738 or 1016F of the Corporations Act at the time that we request that the *securities be quoted.
- If we are a trust, we warrant that no person has the right to return the +securities to be quoted under section 1019B of the Corporations Act at the time that we request that the *+*securities be quoted.
- We will indemnify ASX to the fullest extent permitted by law in respect of any 3 claim, action or expense arising from or connected with any breach of the warranties in this agreement.
- We give ASX the information and documents required by this form. If any 4 information or document is not available now, we will give it to ASX before ⁺quotation of the ⁺securities begins. We acknowledge that ASX is relying on the information and documents. We warrant that they are (will be) true and complete. 1/1

gn here:	Mi	26 July 2019 Date:
8	(Company Secretary)	

Si

Sam Wright

.....

Print name:

== == == == ==

Note: An entity may need to obtain appropriate warranties from subscribers for the securities in order to be able to give this warranty

⁺ See chapter 19 for defined terms.

Appendix 3B – Annexure 1

Calculation of placement capacity under rule 7.1 and rule 7.1A for eligible entities

Introduced 01/08/12 Amended 04/03/13

Part 1

Rule 7.1 – Issues exceeding 15% of capital		
Step 1: Calculate "A", the base figure from which the placement capacity is calculated		
<i>Insert</i> number of fully paid ordinary securities on issue 12 months before date of issue or agreement to issue	200,300,664	
 Add the following: Number of fully paid ordinary securities issued in that 12 month period under an exception in rule 7.2 Number of fully paid ordinary securities issued in that 12 month period with shareholder approval Number of partly paid ordinary securities that became fully paid in that 12 month period 	79,920,528	
 Note: Include only ordinary securities here – other classes of equity securities cannot be added Include here (if applicable) the securities the subject of the Appendix 3B to which this form is annexed It may be useful to set out issues of securities on different dates as separate line items 		
<i>Subtract</i> the number of fully paid ordinary securities cancelled during that 12 month period		
" A "	280,221,192	

⁺ See chapter 19 for defined terms.

Step 2: Calculate 15% of "A"		
"B"	0.15	
	[Note: this value cannot be changed]	
<i>Multiply</i> "A" by 0.15	42,033,179	
Step 3: Calculate "C", the amount of placement capacity under rule 7.1 that has already been used		
<i>Insert</i> number of ⁺ equity securities issued or agreed to be issued in that 12 month period <i>not counting</i> those issued:	1,000,000	
• Under an exception in rule 7.2		
Under rule 7.1A		
 With security holder approval under rule 7.1 or rule 7.4 		
 Note: This applies to equity securities, unless specifically excluded – not just ordinary securities Include here (if applicable) the securities the subject of the Appendix 3B to which this form is annexed It may be useful to set out issues of securities on different dates as separate line items 		
"C"	1,000,000	
Step 4: Subtract "C" from ["A" x "E placement capacity under rule 7.1 "A" x 0.15	3"] to calculate remaining 42,033,179	
Note: number must be same as shown in Step 2		
Subtract "C"	1,000,000	
Note: number must be same as shown in Step 3		
<i>Total</i> ["A" x 0.15] – "C"	41,033,179	
	[Note: this is the remaining placement capacity under rule 7.1]	

⁺ See chapter 19 for defined terms.

Part 2

Rule 7.1A – Additional placement capacity for eligible entities		
Step 1: Calculate "A", the base figure from which the placement capacity is calculated		
" A " 280,221,192		
Note: number must be same as shown in Step 1 of Part 1		
Step 2: Calculate 10% of "A"		
"D"	0.10	
	Note: this value cannot be changed	
<i>Multiply</i> "A" by 0.10	28,022,119	
Step 3: Calculate "E", the amount of placement capacity under rule 7.1A that has already been used		
<i>Insert</i> number of ⁺ equity securities issued or agreed to be issued in that 12 month period under rule 7.1A		
 Notes: This applies to equity securities – not just ordinary securities Include here – if applicable – the securities the subject of the Appendix 3B to which this form is annexed Do not include equity securities issued under rule 7.1 (they must be dealt with in Part 1), or for which specific security holder approval has been obtained It may be useful to set out issues of securities on different dates as separate line items 	Nil	
	NII	

⁺ See chapter 19 for defined terms.

Step 4: Subtract "E" from ["A" x "D"] to calculate remaining placement capacity under rule 7.1A		
"A" x 0.10	28,022,119	
Note: number must be same as shown in Step 2		
Subtract "E"	Nil	
Note: number must be same as shown in Step 3		
<i>Total</i> ["A" x 0.10] – "E"	28,022,119	
	<i>Note: this is the remaining placement capacity under rule 7.1A</i>	

⁺ See chapter 19 for defined terms.